Komori
Business Alliances4563AnGes,Inc.Pharmaceuticals

Notice Regarding the Award of a Grant to Advance Development of the Subcutaneous Formulation of the Co-Developed Tie2 Receptor Agonist (AV-001)

AnGes and Vasomune will receive research and development funding and advisory services from a program run by the National Research Council of Canada for the subcutaneous formulation of AV-001, which they are co-developing. This will advance development of subcutaneous injection in addition to intravenous administration.

Worth reading
54Recurring
Scored from 4 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
280347
Canadian dollar
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Business Alliances
4563AnGes,Inc.
Alliance partnerVasomune Therapeutics, Inc.
Details of the alliance
  1. 1

    Support the development of the subcutaneous formulation of Pegevongitide (the Tie2 receptor agonist AV-001)

  2. 2

    Receive research and development funding and advisory services

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionA private, clinical-stage biopharmaceutical company developing next-generation pharmaceuticals that enhance the body's protective functions against endothelial injury and vascular leakage
LocationToronto, Canada
Agreements reached under this partnership
ItemDetails
Name of alliance partnerVasomune Therapeutics, Inc.
Alliance partner's business activitiesA private, clinical-stage biopharmaceutical company developing next-generation pharmaceuticals that enhance the body's protective functions against endothelial injury and vascular leakage
Alliance partner's locationToronto, Canada
Type of allianceBusiness Alliances
Details of the allianceSupport the development of the subcutaneous formulation of Pegevongitide (the Tie2 receptor agonist AV-001), Receive research and development funding and advisory services
Items this document does not state (18)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateImpact on Business PerformanceChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To expand the options for how and when AV-001 is administered through subcutaneous injection, improve administration convenience, enable rapid therapeutic intervention before arrival at the ICU, and support use in both civilian and military settings.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Award of a Grant to Advance Development of the Subcutaneous Formulation of the Co-Developed Tie2 Receptor Agonist (AV-001) | AnGes,Inc. (4563) timely disclosure | Komori